Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection

被引:134
|
作者
Theil, FP [1 ]
Guentert, TW [1 ]
Haddad, S [1 ]
Poulin, P [1 ]
机构
[1] F Hoffmann La Roche & Co Ltd, Nonclin Drug Safety, Pharma Res, CH-4070 Basel, Switzerland
关键词
drug discovery; drug development; partition coefficients; PBPK modeling; pharmacokinetics; toxicokinetics; QSAR;
D O I
10.1016/S0378-4274(02)00374-0
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
The present paper proposes a modeling and simulation strategy for the prediction of pharmacokinetics (PK) of drug candidates by using currently available in silico and in vitro based prediction tools for absorption, distribution, metabolism and excretion (ADME). These methods can be used to estimate specific ADME parameters (such as rate and extent of absorption into portal vein, volume of distribution, metabolic clearance in the liver). They can also be part of a physiologically based pharmacokinetic (PBPK) model to simulate concentration-time profiles in tissues and plasma resulting from the overall PK after intravenous or oral administration. Since the ADME prediction tools are built only on commonly generated in silico and in vitro data, they can be applied already in early drug discovery, prior to any in vivo study. With the suggested methodology, the following advantages of the mechanistic PBPK modeling framework can now be utilized to explore potential clinical candidates already in drug discovery: (i) prediction of plasma (blood) and tissue PK of drug candidates prior to in vivo experiments, (ii) supporting a better mechanistic understanding of PK properties, as well as helping the development of more rationale PK-PD relationships from tissue kinetic data predicted, and hence facilitating a more rational decision during clinical candidate selection, and (iii) the extrapolation across species, routes of administration and dose levels. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:29 / 49
页数:21
相关论文
共 50 条
  • [21] Impact of Physiologically Based Pharmacokinetic Modeling and Simulation in Drug Development
    Shardlow, Carole E.
    Generaux, Grant T.
    Patel, Aarti H.
    Tai, Guoying
    Thuy Tran
    Bloomer, Jackie C.
    DRUG METABOLISM AND DISPOSITION, 2013, 41 (12) : 1994 - 2003
  • [22] Utility of physiologically based pharmacokinetic modeling in predicting and characterizing clinical drug interactions
    Foti, Robert S.
    DRUG METABOLISM AND DISPOSITION, 2025, 53 (01)
  • [23] Utility of physiologically based pharmacokinetic (PBPK) modeling in oncology drug development and its accuracy: a systematic review
    Teerachat Saeheng
    Kesara Na-Bangchang
    Juntra Karbwang
    European Journal of Clinical Pharmacology, 2018, 74 : 1365 - 1376
  • [24] Utility of physiologically based pharmacokinetic (PBPK) modeling in oncology drug development and its accuracy: a systematic review
    Saeheng, Teerachat
    Na-Bangchang, Kesara
    Karbwang, Juntra
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 74 (11) : 1365 - 1376
  • [25] UTILITY OF PHYSIOLOGICALLY- BASED PHARMACOKINETIC MODELING AND SIMULATION IN DRUG DEVELOPMENT AND CHALLENGES IN REGULATORY REVIEWS.
    Zhao, P.
    Zhang, L.
    Lesko, L.
    Huang, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S72 - S72
  • [26] Drug dosing during pregnancy—opportunities for physiologically based pharmacokinetic models
    Khaled Abduljalil
    Raj K. Singh Badhan
    Journal of Pharmacokinetics and Pharmacodynamics, 2020, 47 : 319 - 340
  • [27] Utility of Physiologically based Pharmacokinetics (PBPK) in Pediatric Drug Development
    Xu, Yan
    Hartmann, Georgy
    Gibson, Christopher
    Frobel, Tina
    Kerbusch, Thomas
    Wrishko, Rebecca
    Kesisoglou, Filippos
    Rooseboom, Martijn
    Reddy, Venkatesh Pilla
    Mitra, Amitava
    Thompson, Karen
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2014, 41 : S27 - S27
  • [28] Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
    Mosely, Suzanne I. S.
    Prime, John E.
    Sainson, Richard C. A.
    Koopmann, Jens-Oliver
    Wang, Dennis Y. Q.
    Greenawalt, Danielle M.
    Ahdesmaki, Miika J.
    Leyland, Rebecca
    Mullins, Stefanie
    Pacelli, Luciano
    Marcus, Danielle
    Anderton, Judith
    Watkins, Amanda
    Ulrichsen, Jane Coates
    Brohawn, Philip
    Higgs, Brandon W.
    McCourt, Matthew
    Jones, Hazel
    Harper, James A.
    Morrow, Michelle
    Valge-Archer, Viia
    Stewart, Ross
    Dovedi, Simon J.
    Wilkinson, Robert W.
    CANCER IMMUNOLOGY RESEARCH, 2017, 5 (01) : 29 - 41
  • [29] Development of a Physiologically Based Pharmacokinetic Model for Itraconazole Pharmacokinetics and Drug-Drug Interaction Prediction
    Chen, Yuan
    Ma, Fang
    Lu, Tong
    Budha, Nageshwar
    Jin, Jin Yan
    Kenny, Jane R.
    Wong, Harvey
    Hop, Cornelis E. C. A.
    Mao, Jialin
    CLINICAL PHARMACOKINETICS, 2016, 55 (06) : 735 - 749
  • [30] Physiologically Based Pharmacokinetic Models of Probenecid and Furosemide to Predict Transporter Mediated Drug-Drug Interactions
    Hannah Britz
    Nina Hanke
    Mitchell E. Taub
    Ting Wang
    Bhagwat Prasad
    Éric Fernandez
    Peter Stopfer
    Valerie Nock
    Thorsten Lehr
    Pharmaceutical Research, 2020, 37